Detalhe da pesquisa
1.
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Future Oncol
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357801
2.
Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data.
Future Oncol
; 18(17): 2063-2074, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35232230
3.
Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design.
Future Oncol
; 18(7): 781-791, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34918546
4.
Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population.
Future Oncol
; 17(1): 103-115, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32959703
5.
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States.
Pharmacoepidemiol Drug Saf
; 30(6): 758-769, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33428292
6.
Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
Cancer Sci
; 111(5): 1724-1738, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32159882
7.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat
; 183(2): 419-428, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32683565
8.
Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer.
Invest New Drugs
; 38(3): 874-884, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31858327
9.
Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival.
Future Oncol
; 16(36): 3107-3116, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32869649
10.
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Future Oncol
; 16(1): 4289-4301, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31778074
11.
Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer.
Future Oncol
; 15(10): 1097-1103, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30652510
12.
Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer.
Future Oncol
; 15(24): 2857-2871, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31298572
13.
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
Anticancer Drugs
; 29(3): 271-280, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29360661
14.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
N Engl J Med
; 371(23): 2167-77, 2014 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-25470694
15.
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
N Engl J Med
; 371(21): 1963-71, 2014 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25264305
16.
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
N Engl J Med
; 368(25): 2385-94, 2013 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724913
17.
Acquired resistance to crizotinib from a mutation in CD74-ROS1.
N Engl J Med
; 368(25): 2395-401, 2013 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724914
18.
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Blood
; 119(20): 4597-607, 2012 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22383795
19.
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Lancet Oncol
; 14(6): 472-80, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23598171
20.
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
N Engl J Med
; 363(18): 1727-33, 2010 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-20979472